JPRN-jRCT2041230156招募中3 期
A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients with Acquired Hypothalamic Obesity
Flaherty Jim0 个研究点目标入组 12 人开始时间: 2024年2月22日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 4age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Patient has documented evidence of acquired HO
- •2.Aged 4 years and older
- •3.Documented weight gain associated with the hypothalamic injury either, and a body mass index (BMI) of >-30 kg/m2 for patients >-18 years of age, or BMI>-95th percentile for age and sex for patients 4 to <18 years of age
- •4.A highly effective form of contraception must be used/practiced throughout the trial and for 90 days
- •5.If receiving hormone replacement therapy, the dose of such therapy has remained stable for at least 2 months prior to Screening
- •Other protocol defined Inclusion criteria may apply.
排除标准
- •1.Diagnosis of Prader-Willi syndrome (PWS) or Rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, neuroendocrine tumor syndrome (ROHHADNET)
- •2.Weight loss >2% in the previous 3 months for patients aged >-18 years or >2% reduction in BMI for patients aged 4 to <18 years
- •3.Bariatric surgery or procedure within the last 2 years
- •4.Diagnosis of severe psychiatric disorders, or any suicidal ideation, attempts, or any suicidal
- •5.Current, clinically significant pulmonary, cardiac, metabolic, or oncologic disease considered
- •6.Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion)
- •7.History or close family history of skin cancer or melanoma
- •8.Participation in any clinical trial with an investigational drug/device within 3 months, prior to the first trial dose
- •9.Previously enrolled in a clinical trial involving setmelanotide or any previous exposure to setmelanotide
- •10.Inability to comply with once daily (QD) injection regimen
- •11.Pregnant and/or breastfeeding
- •12.Patients with obesity attributable to other genetic or syndromic conditions (eg, PPL [POMC, PCSK1, LEPR, collectively], BBS) prior to the hypothalamic injury
- •Other protocol defined Exclusion criteria may apply.
研究者
相似试验
招募中
1 期
Phase 3 Trial of Setmelanotide in Acquired Hypothalamic ObesityAcquired Hypothalamic ObesityCTIS2022-503116-16-00Rhythm Pharmaceuticals Inc.120
进行中（未招募）
不适用
A phase 3 clinical Study verifying if a noval anti-viral drug called favipiravir is safe and works well in adult patients that have a simple influenza infection.ncomplicated influenza.MedDRA version: 17.0Level: LLTClassification code 10060078Term: Influenza serology positiveSystem Organ Class: 100000004848EUCTR2013-002149-13-HUMDVI, LLC660
进行中（未招募）
不适用
A phase 3 clinical Study verifying if a noval anti-viral drug called favipiravir is safe and works well in adult patients that have a simple influenza infection.EUCTR2013-002149-13-BEMDVI, LLC660
进行中（未招募）
不适用
A phase 3 clinical Study verifying if a noval anti-viral drug called favipiravir is safe and works well in adult patients that have a simple influenza infection.EUCTR2013-002149-13-NLMDVI, LLC660
进行中（未招募）
1 期
A phase 3 clinical Study verifying if a noval anti-viral drug called favipiravir is safe and works well in adult patients that have a simple influenza infection.ncomplicated influenza.MedDRA version: 17.1Level: LLTClassification code 10060078Term: Influenza serology positiveSystem Organ Class: 100000004848EUCTR2013-002149-13-SEMDVI, LLC660